The discovery of thrombolytic agents goes back to the 1930s, when it was shown that substances derived from bacteria (streptokinase, staphylokinase), tissue (fibrinokinase), urine (urokinase) or bat saliva could activate the fibrinolytic system. The potential to treat arterial thrombosis with plasmin was recognized, but it was not until 1958 that its first use in acute ischaemic stroke (AIS) was described. However, since computer tomography (CT) was not available until the mid 1970s, optimal selection of patients was not possible. Early studies with streptokinase in AIS showed an increased risk of intracranial haemorrhage and lack of efficacy, which was associated with low fibrin specificity. The search for new agents with a better risk-benefit profile continued until 1979 when tissue plasminogen activator (t-PA) was discovered. In 1983 it became possible to produce recombinant t-PA (rt-PA) by expression of a cloned gene which enabled clinical trials to be started, mainly for coronary thrombolysis. In 1995, the National Institute of Neurological Disorders and Stroke study showed that rt-PA was an effective treatment for AIS, nowadays for use up to 4.5 h after onset. However, rt-PA still often fails in achieving rapid reperfusion, has relatively low recanalization rates and is associated with an increased bleeding risk. Several attempts have been made to develop thrombolytics with a better risk-benefit profile than rt-PA, but no real impact on clinical practice was observed. In 1994, it was shown that tenecteplase (rt-PA-TNK) had a higher fibrin specificity than rt-PA, but its clinical use in AIS was described only in 2005. The recently reported results of a small phase 2B trial showed significantly better reperfusion and clinical outcome with rt-PA-TNK compared to rt-PA; patients were selected by CT perfusion and angiography, and treated within 6 h after stroke onset. Currently, a phase 3 trial of rt-PA-TNK versus rt-PA is being planned in patients at an onset up to 4.5 h. The most fibrin-specific recombinant plasminogen activator desmoteplase originates from 1991, and its clinical development in AIS started in 2005. Desmoteplase is in phase 3 development for the treatment of AIS between 3 and 9 h after onset in AIS patients presenting with occlusion or high-grade stenosis.

1.
Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. Lancet 2008;371:1612-1623.
2.
Collen D, Lijnen HR: Thrombolytic agents. Thromb Haemost 2005;93:627-630.
3.
Rijken DC, Collen D: Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981;256:7035-7041.
4.
Collen D, Lijnen HR: Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004;2:541-546.
5.
Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
6.
Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, et al: Stroke: working toward a prioritized world agenda. Cerebrovasc Dis 2010;30:127-147.
7.
Kaste M: Stroke: advances in thrombolysis. Lancet Neurol 2013;12:2-4.
8.
Tillett WS, Garner RL: The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502.
9.
Ouriel K: A history of thrombolytic therapy. J Endovasc Ther 2004;11(suppl 2):II128-II133.
10.
Sikri N, Bardia A: A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007;34:318-327.
11.
Tillett WS, Johnson AJ, McCarty WR: The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients. J Clin Invest 1955;34:169-185.
12.
Macfarlane RG, Pilling J: Fibrinolytic activity of normal urine. Nature 1947;159:779.
13.
Lack CH: Staphylokinase: an activator of plasma protease. Nature 1948;161:559.
14.
Sussman BJ, Fitch TS: Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958;167:1705-1709.
15.
Fletcher AP, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks JE, et al: A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135-142.
16.
Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963;13:927-937.
17.
Meyer JS, Gilroy J, Barnhart MI, Johnson JF: Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964;189:373.
18.
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Lancet 1995;346:1509-1514.
19.
Thrombolytic therapy with streptokinase in acute ischemic stroke: Multicenter Acute Stroke Trial - Europe study group. N Engl J Med 1996;335:145-150.
20.
Fujishima M, Omae T, Tanaka K, Iino K, Matsuo O, Mihara H: Controlled trial of combined urokinase and dextran sulfate therapy in patients with acute cerebral infarction. Angiology 1986;37:487-498.
21.
Wardlaw JM, Warlow CP: Thrombolysis in acute ischemic stroke: does it work? Stroke 1992;23:1826-1839.
22.
Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, et al: Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984;310:609-613.
23.
Van de Werf F, Bergmann SR, Fox KA, de Geest H, Hoyng CF, Sobel BE, et al: Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984;69:605-610.
24.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction: The GUSTO investigators. N Engl J Med 1993;329:673-682.
25.
Terashi A, Kobayashi Y, Katayama Y, Inamura K, Kazama M, Abe T: Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost 1990;16:236-241.
26.
Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 min. Stroke 1992;23:632-640.
27.
Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 min from onset. Stroke 1992;23:641-645.
28.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
29.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
30.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
31.
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-2026.
32.
Clark WM, Albers GW, Madden KP, Hamilton S: The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276 g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic Therapy in Acute Ischemic Stroke Study investigators. Stroke 2000;31:811-816.
33.
Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299-309.
34.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-1703.
35.
Shobha N, Buchan AM, Hill MD: Thrombolysis at 3-4.5 h after acute ischemic stroke onset - evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-228.
36.
Parsons MW: Treating as early as possible with thrombolysis is crucial, but can we do better in the sub-4.5-hour time window? Cerebrovasc Dis 2011;31:229.
37.
Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-2948.
38.
Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al: Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-1309.
39.
Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al: Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-874.
40.
Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al: Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. Br Med J 2010;341:c6046.
41.
Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, et al: Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010;41:2568-2574.
42.
Mishra NK, Davis SM, Kaste M, Lees KR: Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010;33:2531-2537.
43.
Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al: The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke [the Third International Stroke Trial (IST-3)]: a randomised controlled trial. Lancet 2012;379:2352-2363.
44.
Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan Post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-1989.
45.
Micieli G, Marcheselli S, Tosi PA: Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag 2009;5:397-409.
46.
Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL: t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012;119:4752-4761.
47.
Tsikouris JP, Tsikouris AP: A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001;21:207-217.
48.
Molina CA: Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 2011;42(suppl):S16-S19.
49.
Planas AM, Traystman RJ: Advances in translational medicine 2010. Stroke 2011;42:283-284.
50.
Schellinger PD, Kohrmann M: Current acute stroke trials and their potential impact on the therapeutic time window. Expert Rev Neurother 2012;12:169-177.
51.
Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Assoc 1999;282:2003-2011.
52.
Medcalf RL, Davis SM: Plasminogen activation and thrombolysis for ischemic stroke. Int J Stroke 2012;7:419-425.
53.
Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, et al: New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-3040.
54.
Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM: A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:607-612.
55.
Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A, Attia J, et al: Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009;72:915-921.
56.
Lyden P: Tenecteplase for acute ischemic stroke. Int J Stroke 2011;6:509-510.
57.
Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al: A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099-1107.
58.
Bier O: Action anticoagulante et fibrinolytique de l'extract des glands salivaires d'une chauve-souris hématophage (Desmodus rufus). C R Soc Biol (Paris) 1932;110:129-131.
59.
Kratzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, et al: The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991;105:229-237.
60.
Medcalf RL: Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012;165:75-89.
61.
Paciaroni M, Medeiros E, Bogousslavsky J: Desmoteplase. Expert Opin Biol Ther 2009;9:773-778.
62.
Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, et al: Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270:25596-25603.
63.
Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 h after stroke onset. Stroke 2006;37:1227-1231.
64.
Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
65.
Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al: Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-150.
66.
Fiebach JB, Al-Rawi Y, Wintermark M, Furlan AJ, Rowley HA, Lindsten A, et al: Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012;43:1561-1566.
67.
Von Kummer R, Albers GW, Mori E: The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke 2012;7:589-596.
68.
Saver JL. Time is brain - quantified. Stroke 2006;37:263-266.
69.
Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ, Ford GA: Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003;34:71-76.
70.
Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al: The ‘golden hour' and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 min of stroke onset. Stroke 2010;41:1431-1439.
71.
Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW: How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 2011;7:400-409.
72.
Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M: Reducing in-hospital delay to 20 min in stroke thrombolysis. Neurology 2012;79:306-313.
73.
Baron JC, von Kummer R, del Zoppo GJ: Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke 1995;26:2219-2221.
74.
Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, et al: Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 h. Stroke 2002;33:2438-2445.
75.
Muir KW, Buchan A, von Kummer R, Rother J, Baron JC: Imaging of acute stroke. Lancet Neurol 2006;5:755-768.
76.
Gralla J, Brekenfeld C, Mordasini P, Schroth G: Mechanical thrombolysis and stenting in acute ischemic stroke. Stroke 2012;43:280-285.
77.
Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al: Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241-1249.
78.
Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-517.
79.
Sandercock P, Wardlaw J, Lindley R: Where are we now with intravenous thrombolysis for acute ischaemic stroke? Int J Stroke 2010;5:381-382.
80.
Wang Y, Liao X, Zhao X, Wang C, Liu L, Zhou Y, et al: Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II). Int J Stroke 2009;4:49-53.
81.
Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, et al: A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012;7:74-80.
82.
Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al: Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-2372.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.